The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Why HER2 testing matters in newly diagnosed biliary tract cancer
Choong-kun Lee, MD, PhD, Yonsei University College of Medicine, Seoul, South Korea, discusses the importance of HER2 immunohistochemistry testing for newly diagnosed patients with biliary tract cancer (BTC), particularly those with metastatic or locally unresectable disease, as HER2-positive patients have worse prognoses. HER2-positive patients require anti-HER2 agents in their treatment and incorporating HER2-targeting strategies into frontline treatment may provide more benefits. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
In our center, we perform the HER2 immunohistochemistry for every newly diagnosed biliary cancer patient. And I know that it’s not standard of care for any other centers, but I believe that HER2 testing at the very first, when they’re diagnosed, especially for the patient with the metastatic or locally unresectable disease, it will be the essential thing as this kind of patient, this HER2-positive biliary cancer patient has worse prognoses...
In our center, we perform the HER2 immunohistochemistry for every newly diagnosed biliary cancer patient. And I know that it’s not standard of care for any other centers, but I believe that HER2 testing at the very first, when they’re diagnosed, especially for the patient with the metastatic or locally unresectable disease, it will be the essential thing as this kind of patient, this HER2-positive biliary cancer patient has worse prognoses. And we have recently published a paper saying that this kind of HER2-positive biliary cancer definitely needs anti-HER2 agents in their treatment journey. So I think moving this HER2-targeting strategy into the front line will give them more benefit. So I think it’s definitely needed.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
